Biomérieux competitors

Accredited public company director. Dynamic, creative, growth and success oriented leader. Proven experience building and leading an organization from distress to profitability while increasing shareholder value 5x in 24 months.

Timothy R. Wright is the President and CEO of M2Gen®. He was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva. Mr. Wright is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, where he previously served as Director. He is a current a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright has served in executive leadership roles at several pharmaceutical firms, including Covidien, Elan, and DuPont Merck. He holds a B.Sc. from The Ohio State University.

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

Jean-Claude Dubacher is Chairman and CEO of B. Braun of America Inc., which includes B. Braun Medical Inc., B. Braun Interventional Systems, Aesculap® and CAPS®. Mr. Dubacher joined B. Braun in August 2019 as President, B. Braun Medical Inc., and has served as Chairman and Chief Executive Officer of B. Braun Medical Inc. since January 1, 2020. Dubacher’s experience in healthcare spans more than 15 years in consulting and corporate roles including strategy, commercial, supply chain and manufacturing. Prior to joining B. Braun, Dubacher led commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson (formerly Abbott Medical Optics) in Europe. Throughout his career, Mr. Dubacher has demonstrated a passion for focusing on customer needs and supporting people to be successful in developing, manufacturing, marketing, and selling products and services that benefit patients. Dubacher holds a Doctorate Degree in law (Dr. iur.) from the University of Zurich in Switzerland, and an MBA from Harvard Business School. He is a board member for the German American Chamber of Commerce.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Speck Loe works at Medimmune and a Ceo at Medimmune and is based in Granite Falls, Washington.